Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiovascular Diseases | 15 | 2023 | 1059 | 3.790 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2019 | 133 | 2.960 |
Why?
|
Dyslipidemias | 5 | 2023 | 54 | 2.310 |
Why?
|
Practice Guidelines as Topic | 10 | 2018 | 369 | 1.970 |
Why?
|
Troponin T | 4 | 2019 | 56 | 1.880 |
Why?
|
Risk Assessment | 12 | 2019 | 1285 | 1.810 |
Why?
|
Heart Failure | 6 | 2017 | 574 | 1.780 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 2019 | 9 | 1.760 |
Why?
|
Diabetes Mellitus | 7 | 2023 | 366 | 1.550 |
Why?
|
Hypertension | 7 | 2023 | 978 | 1.390 |
Why?
|
Myocardial Infarction | 7 | 2017 | 418 | 1.360 |
Why?
|
Cardiology | 4 | 2017 | 73 | 1.340 |
Why?
|
United States | 24 | 2023 | 3588 | 1.310 |
Why?
|
Cholesterol, LDL | 3 | 2019 | 165 | 1.290 |
Why?
|
Guideline Adherence | 7 | 2018 | 110 | 1.280 |
Why?
|
American Heart Association | 4 | 2017 | 81 | 1.280 |
Why?
|
Hospitalization | 4 | 2017 | 386 | 1.260 |
Why?
|
Registries | 10 | 2019 | 269 | 1.240 |
Why?
|
Atherosclerosis | 6 | 2022 | 725 | 1.230 |
Why?
|
Football | 4 | 2014 | 69 | 1.180 |
Why?
|
Male | 40 | 2023 | 16967 | 1.170 |
Why?
|
Middle Aged | 30 | 2020 | 10678 | 1.140 |
Why?
|
Retirement | 3 | 2014 | 10 | 1.130 |
Why?
|
Humans | 50 | 2023 | 28304 | 1.080 |
Why?
|
Cognition | 2 | 2019 | 512 | 1.060 |
Why?
|
Female | 36 | 2023 | 17679 | 1.020 |
Why?
|
Stroke Volume | 2 | 2017 | 278 | 0.990 |
Why?
|
Risk Factors | 21 | 2019 | 3520 | 0.980 |
Why?
|
Carotid Artery Diseases | 2 | 2014 | 114 | 0.930 |
Why?
|
Coronary Artery Disease | 4 | 2016 | 379 | 0.900 |
Why?
|
Lipoprotein(a) | 2 | 2019 | 10 | 0.860 |
Why?
|
Intermittent Claudication | 2 | 2018 | 9 | 0.830 |
Why?
|
Health Status | 4 | 2017 | 360 | 0.820 |
Why?
|
Cholesterol | 3 | 2017 | 231 | 0.790 |
Why?
|
Coronary Disease | 3 | 2016 | 205 | 0.790 |
Why?
|
Aged | 22 | 2019 | 9256 | 0.760 |
Why?
|
C-Reactive Protein | 3 | 2017 | 236 | 0.760 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2019 | 55 | 0.710 |
Why?
|
Apolipoproteins B | 1 | 2019 | 44 | 0.700 |
Why?
|
Obesity | 4 | 2023 | 1079 | 0.680 |
Why?
|
Cognition Disorders | 2 | 2019 | 388 | 0.670 |
Why?
|
Hyperlipoproteinemia Type II | 2 | 2016 | 13 | 0.670 |
Why?
|
Cardiovascular Agents | 2 | 2016 | 19 | 0.660 |
Why?
|
Time Factors | 13 | 2019 | 1874 | 0.660 |
Why?
|
Adult | 16 | 2023 | 8243 | 0.620 |
Why?
|
Hospital Costs | 1 | 2017 | 33 | 0.600 |
Why?
|
Health Status Disparities | 1 | 2018 | 105 | 0.600 |
Why?
|
Inflammation Mediators | 1 | 2017 | 101 | 0.600 |
Why?
|
Mortality | 1 | 2017 | 108 | 0.590 |
Why?
|
Triglycerides | 1 | 2017 | 220 | 0.590 |
Why?
|
Medication Therapy Management | 1 | 2016 | 12 | 0.590 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 54 | 0.590 |
Why?
|
Forecasting | 1 | 2017 | 130 | 0.580 |
Why?
|
Cardiomyopathies | 1 | 2016 | 49 | 0.580 |
Why?
|
Blood Pressure | 5 | 2020 | 861 | 0.570 |
Why?
|
Prospective Studies | 9 | 2019 | 1932 | 0.570 |
Why?
|
Inservice Training | 1 | 2016 | 11 | 0.560 |
Why?
|
United States Department of Veterans Affairs | 1 | 2016 | 49 | 0.560 |
Why?
|
Exercise Therapy | 1 | 2018 | 195 | 0.560 |
Why?
|
Body Mass Index | 3 | 2019 | 890 | 0.560 |
Why?
|
Ambulatory Care Facilities | 1 | 2016 | 62 | 0.550 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 45 | 0.550 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2016 | 317 | 0.550 |
Why?
|
Apolipoprotein C-III | 1 | 2015 | 3 | 0.550 |
Why?
|
Peptide Fragments | 1 | 2019 | 480 | 0.540 |
Why?
|
Lipoprotein Lipase | 1 | 2015 | 14 | 0.540 |
Why?
|
Proprotein Convertases | 1 | 2015 | 2 | 0.540 |
Why?
|
Hypercholesterolemia | 1 | 2016 | 61 | 0.530 |
Why?
|
Acute Coronary Syndrome | 1 | 2017 | 175 | 0.530 |
Why?
|
Diabetes Complications | 1 | 2016 | 184 | 0.530 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 113 | 0.520 |
Why?
|
Waist Circumference | 1 | 2014 | 90 | 0.500 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 201 | 0.500 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 147 | 0.500 |
Why?
|
Comorbidity | 7 | 2017 | 531 | 0.500 |
Why?
|
Attitude of Health Personnel | 1 | 2016 | 152 | 0.500 |
Why?
|
Occupations | 1 | 2014 | 10 | 0.500 |
Why?
|
Healthcare Disparities | 1 | 2016 | 148 | 0.490 |
Why?
|
Neck | 1 | 2014 | 26 | 0.490 |
Why?
|
Athletes | 1 | 2014 | 62 | 0.480 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2019 | 79 | 0.480 |
Why?
|
European Continental Ancestry Group | 1 | 2018 | 1203 | 0.460 |
Why?
|
Treatment Outcome | 11 | 2019 | 2886 | 0.450 |
Why?
|
Incidence | 5 | 2019 | 1087 | 0.430 |
Why?
|
Prognosis | 4 | 2017 | 1342 | 0.380 |
Why?
|
African Americans | 1 | 2018 | 1513 | 0.380 |
Why?
|
Lipids | 3 | 2017 | 215 | 0.370 |
Why?
|
Cohort Studies | 5 | 2017 | 1673 | 0.370 |
Why?
|
Drug-Eluting Stents | 3 | 2017 | 16 | 0.360 |
Why?
|
Follow-Up Studies | 5 | 2019 | 2027 | 0.360 |
Why?
|
Calcinosis | 3 | 2014 | 158 | 0.350 |
Why?
|
Stents | 3 | 2017 | 131 | 0.340 |
Why?
|
Calcium | 3 | 2014 | 276 | 0.330 |
Why?
|
Logistic Models | 6 | 2017 | 727 | 0.330 |
Why?
|
Linear Models | 4 | 2017 | 421 | 0.330 |
Why?
|
Prevalence | 6 | 2017 | 881 | 0.330 |
Why?
|
Quality of Life | 3 | 2018 | 792 | 0.320 |
Why?
|
Proportional Hazards Models | 4 | 2017 | 706 | 0.300 |
Why?
|
Predictive Value of Tests | 4 | 2017 | 774 | 0.300 |
Why?
|
Postprandial Period | 2 | 2016 | 10 | 0.280 |
Why?
|
Health Services Accessibility | 2 | 2020 | 226 | 0.280 |
Why?
|
Decision Support Techniques | 2 | 2017 | 103 | 0.280 |
Why?
|
Chi-Square Distribution | 5 | 2017 | 293 | 0.280 |
Why?
|
Drug Prescriptions | 2 | 2016 | 52 | 0.270 |
Why?
|
Coronary Angiography | 3 | 2017 | 140 | 0.270 |
Why?
|
Metals | 2 | 2017 | 16 | 0.250 |
Why?
|
Southeastern United States | 1 | 2023 | 79 | 0.240 |
Why?
|
Family Practice | 1 | 2023 | 41 | 0.240 |
Why?
|
Multivariate Analysis | 4 | 2017 | 631 | 0.230 |
Why?
|
Coronary Vessels | 2 | 2014 | 161 | 0.230 |
Why?
|
Self Efficacy | 1 | 2023 | 64 | 0.230 |
Why?
|
Medical History Taking | 1 | 2022 | 32 | 0.220 |
Why?
|
Refugees | 1 | 2022 | 5 | 0.220 |
Why?
|
India | 3 | 2016 | 62 | 0.210 |
Why?
|
Odds Ratio | 4 | 2016 | 457 | 0.210 |
Why?
|
Aged, 80 and over | 6 | 2019 | 3562 | 0.200 |
Why?
|
Hemorrhage | 2 | 2019 | 86 | 0.200 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 370 | 0.190 |
Why?
|
North Carolina | 2 | 2023 | 1412 | 0.190 |
Why?
|
Health Facilities | 1 | 2020 | 11 | 0.190 |
Why?
|
Respiratory Tract Diseases | 1 | 2020 | 30 | 0.190 |
Why?
|
Up-Regulation | 2 | 2017 | 180 | 0.190 |
Why?
|
Sodium Chloride, Dietary | 1 | 2020 | 30 | 0.180 |
Why?
|
Protein Precursors | 1 | 2019 | 18 | 0.180 |
Why?
|
Models, Statistical | 2 | 2017 | 157 | 0.180 |
Why?
|
Metabolic Diseases | 1 | 2019 | 17 | 0.180 |
Why?
|
Peripheral Vascular Diseases | 1 | 2019 | 35 | 0.180 |
Why?
|
Emigration and Immigration | 1 | 2019 | 32 | 0.170 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2022 | 272 | 0.170 |
Why?
|
Apolipoprotein E4 | 1 | 2019 | 58 | 0.170 |
Why?
|
Severity of Illness Index | 4 | 2014 | 846 | 0.170 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 1345 | 0.170 |
Why?
|
Thinness | 1 | 2019 | 31 | 0.170 |
Why?
|
Secondary Prevention | 1 | 2019 | 58 | 0.170 |
Why?
|
Drug Therapy, Combination | 2 | 2017 | 279 | 0.170 |
Why?
|
Lower Extremity | 1 | 2019 | 89 | 0.160 |
Why?
|
Canada | 1 | 2018 | 43 | 0.160 |
Why?
|
Sensitivity and Specificity | 2 | 2016 | 521 | 0.160 |
Why?
|
Recovery of Function | 1 | 2018 | 174 | 0.150 |
Why?
|
Coronary Restenosis | 2 | 2017 | 13 | 0.150 |
Why?
|
Cholesterol, HDL | 1 | 2017 | 170 | 0.150 |
Why?
|
Exercise Tolerance | 1 | 2018 | 110 | 0.150 |
Why?
|
Cause of Death | 1 | 2017 | 219 | 0.150 |
Why?
|
Anticholesteremic Agents | 1 | 2017 | 37 | 0.150 |
Why?
|
Patient Preference | 1 | 2017 | 37 | 0.150 |
Why?
|
Drug Utilization | 1 | 2016 | 48 | 0.140 |
Why?
|
Disease Management | 1 | 2017 | 105 | 0.140 |
Why?
|
Cerebrovascular Disorders | 1 | 2016 | 45 | 0.140 |
Why?
|
Heterozygote | 1 | 2016 | 54 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 436 | 0.140 |
Why?
|
Texas | 1 | 2016 | 40 | 0.140 |
Why?
|
Veterans | 1 | 2016 | 50 | 0.140 |
Why?
|
Transients and Migrants | 1 | 2019 | 275 | 0.140 |
Why?
|
Double-Blind Method | 1 | 2017 | 480 | 0.140 |
Why?
|
Retrospective Studies | 3 | 2022 | 2930 | 0.140 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 61 | 0.140 |
Why?
|
Developing Countries | 1 | 2016 | 40 | 0.140 |
Why?
|
Longitudinal Studies | 1 | 2017 | 694 | 0.140 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 100 | 0.130 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 20 | 0.130 |
Why?
|
Brain Ischemia | 1 | 2016 | 105 | 0.130 |
Why?
|
Monocytes | 1 | 2016 | 119 | 0.130 |
Why?
|
Ambulatory Care | 1 | 2016 | 96 | 0.130 |
Why?
|
Feasibility Studies | 1 | 2016 | 247 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 156 | 0.130 |
Why?
|
Genetic Markers | 1 | 2015 | 134 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 441 | 0.130 |
Why?
|
Societies, Medical | 1 | 2015 | 146 | 0.130 |
Why?
|
Hyperlipidemias | 1 | 2015 | 52 | 0.130 |
Why?
|
Genetic Testing | 1 | 2015 | 93 | 0.130 |
Why?
|
Databases, Factual | 1 | 2016 | 320 | 0.130 |
Why?
|
Alleles | 1 | 2015 | 273 | 0.130 |
Why?
|
Survival Rate | 1 | 2016 | 775 | 0.130 |
Why?
|
Ultrasonography, Doppler | 1 | 2014 | 18 | 0.120 |
Why?
|
Anthropometry | 1 | 2014 | 83 | 0.120 |
Why?
|
Primary Health Care | 1 | 2016 | 174 | 0.120 |
Why?
|
Carotid Stenosis | 1 | 2014 | 49 | 0.120 |
Why?
|
Angioplasty, Balloon | 1 | 2013 | 30 | 0.120 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 378 | 0.120 |
Why?
|
Apoptosis | 1 | 2015 | 333 | 0.120 |
Why?
|
Clinical Competence | 1 | 2016 | 296 | 0.110 |
Why?
|
Mutation | 1 | 2015 | 451 | 0.110 |
Why?
|
Young Adult | 2 | 2017 | 2321 | 0.110 |
Why?
|
Coronary Thrombosis | 1 | 2012 | 15 | 0.110 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 1556 | 0.110 |
Why?
|
Mass Screening | 1 | 2014 | 218 | 0.110 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 313 | 0.110 |
Why?
|
Smoking | 1 | 2014 | 389 | 0.100 |
Why?
|
Inflammation | 1 | 2014 | 501 | 0.100 |
Why?
|
Stroke | 1 | 2015 | 443 | 0.100 |
Why?
|
Nepal | 2 | 2020 | 9 | 0.100 |
Why?
|
Thrombosis | 1 | 2011 | 58 | 0.100 |
Why?
|
Prosthesis Design | 2 | 2017 | 87 | 0.060 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2022 | 9 | 0.060 |
Why?
|
Bhutan | 1 | 2022 | 1 | 0.050 |
Why?
|
Adolescent | 2 | 2022 | 3184 | 0.050 |
Why?
|
Focus Groups | 1 | 2022 | 97 | 0.050 |
Why?
|
Public Sector | 1 | 2020 | 2 | 0.050 |
Why?
|
Private Sector | 1 | 2020 | 8 | 0.050 |
Why?
|
Respiration Disorders | 1 | 2020 | 8 | 0.050 |
Why?
|
World Health Organization | 1 | 2020 | 14 | 0.050 |
Why?
|
Health Resources | 1 | 2020 | 32 | 0.050 |
Why?
|
Medication Adherence | 1 | 2022 | 146 | 0.050 |
Why?
|
Urban Population | 1 | 2020 | 80 | 0.050 |
Why?
|
Health Surveys | 1 | 2020 | 189 | 0.050 |
Why?
|
Sweden | 1 | 2019 | 14 | 0.050 |
Why?
|
Middle East | 1 | 2019 | 5 | 0.040 |
Why?
|
Asia | 1 | 2019 | 17 | 0.040 |
Why?
|
Hemoglobins | 1 | 2019 | 42 | 0.040 |
Why?
|
Policy Making | 1 | 2019 | 18 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2019 | 61 | 0.040 |
Why?
|
Netherlands | 1 | 2018 | 20 | 0.040 |
Why?
|
Australia | 1 | 2018 | 27 | 0.040 |
Why?
|
Rural Population | 1 | 2020 | 244 | 0.040 |
Why?
|
Spain | 1 | 2017 | 3 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2019 | 180 | 0.040 |
Why?
|
Executive Function | 1 | 2017 | 51 | 0.040 |
Why?
|
Missouri | 1 | 2017 | 12 | 0.040 |
Why?
|
Retreatment | 1 | 2017 | 32 | 0.040 |
Why?
|
Drug Costs | 1 | 2017 | 42 | 0.040 |
Why?
|
Disease Progression | 1 | 2018 | 566 | 0.040 |
Why?
|
Patient Participation | 1 | 2017 | 60 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2017 | 166 | 0.040 |
Why?
|
Early Diagnosis | 1 | 2016 | 60 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 116 | 0.030 |
Why?
|
Down-Regulation | 1 | 2016 | 138 | 0.030 |
Why?
|
Patient Selection | 1 | 2017 | 249 | 0.030 |
Why?
|
Anticoagulants | 1 | 2016 | 119 | 0.030 |
Why?
|
Outpatients | 1 | 2015 | 49 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 196 | 0.030 |
Why?
|
Endarterectomy, Carotid | 1 | 2014 | 28 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2014 | 33 | 0.030 |
Why?
|
X-Ray Microtomography | 1 | 2014 | 40 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 96 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2014 | 89 | 0.030 |
Why?
|
Phenotype | 1 | 2016 | 653 | 0.030 |
Why?
|
Pilot Projects | 1 | 2015 | 437 | 0.030 |
Why?
|
Age Factors | 1 | 2016 | 1058 | 0.030 |
Why?
|
Myocardial Reperfusion | 1 | 2012 | 10 | 0.030 |
Why?
|
Ticlopidine | 1 | 2012 | 16 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2014 | 515 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 229 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2012 | 136 | 0.030 |
Why?
|
Health Status Indicators | 1 | 2012 | 68 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 938 | 0.030 |
Why?
|
Propensity Score | 1 | 2011 | 34 | 0.020 |
Why?
|
Sirolimus | 1 | 2011 | 31 | 0.020 |
Why?
|
Paclitaxel | 1 | 2011 | 49 | 0.020 |
Why?
|
Recurrence | 1 | 2011 | 210 | 0.020 |
Why?
|